LHRH-Conjugated Magnetite Nanoparticles and Nanorods as Magnetic Resonance Imaging Contrast Agents for Targeting Triple-Negative Breast Cancer

LHRH偶联磁铁矿纳米颗粒和纳米棒作为磁共振成像造影剂靶向三阴性乳腺癌

阅读:4

Abstract

This paper presents the results of an experimental study on the effects of magnetite nanoparticle (MNP) shape on magnetic resonance imaging (MRI) of triple-negative breast cancer (TNBC) xenograft tissues. T(2)-weighted MRI scans using spherical shaped MNPs as contrast agents are compared to MRI scans done with nanorod-shaped MNPs as contrast agents. The MNPs were first coated with polyethylene glycol (PEG) and subsequently conjugated to luteinizing hormone-releasing hormone (LHRH) to specifically target LHRH receptors, which are present at high levels on the surfaces of xenograft TNBC cells/tissues. After 3 weeks of tumor growth in nude immunocompromised mice, LHRH-conjugated (functionalized) and unconjugated (non-functionalized) MNPs were injected into the immunocompromised mice. Four types of MNPs were used: non-functionalized nanorod-shaped MNPs (BMNR); LHRH-conjugated nanorod-shaped MNPs (LCMNR); non-functionalized spherical-shaped MNPs (BSSMNP); and LHRH-conjugated spherical-shaped MNPs (LCSSMNP). T(2)-weighted magnetic resonance imaging (MRI) scans were obtained from the mice before the injection of the MNPs and two hours after the injection of the MNPs. The results show that using nanorod-shaped LHRH-conjugate MNPs as contrast agents yielded higher-resolution T(2)-weighted MRI scans of TNBC tumors compared to those from spherical-shaped MNPs. The implications of the results are discussed in relation to potential applications of functionalized MNPs in MRI for TNBC diagnosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。